157 related articles for article (PubMed ID: 36564758)
21. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.
Sato A; Okada M; Shibuya K; Watanabe E; Seino S; Narita Y; Shibui S; Kayama T; Kitanaka C
Stem Cell Res; 2014 Jan; 12(1):119-31. PubMed ID: 24185179
[TBL] [Abstract][Full Text] [Related]
22. Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells.
Ganguly D; Sims M; Cai C; Fan M; Pfeffer LM
Stem Cells; 2018 Dec; 36(12):1804-1815. PubMed ID: 30171737
[TBL] [Abstract][Full Text] [Related]
23. Cyclophilin A Maintains Glioma-Initiating Cell Stemness by Regulating Wnt/β-Catenin Signaling.
Wang G; Shen J; Sun J; Jiang Z; Fan J; Wang H; Yu S; Long Y; Liu Y; Bao H; Zhang KX; Han K; Zhu M; Zheng Y; Lin Z; Jiang C; Guo M
Clin Cancer Res; 2017 Nov; 23(21):6640-6649. PubMed ID: 28790108
[No Abstract] [Full Text] [Related]
24. Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression.
Gopinath S; Malla R; Alapati K; Gorantla B; Gujrati M; Dinh DH; Rao JS
Carcinogenesis; 2013 Mar; 34(3):550-9. PubMed ID: 23222817
[TBL] [Abstract][Full Text] [Related]
25. FHL3 links cell growth and self-renewal by modulating SOX4 in glioma.
Han W; Hu P; Wu F; Wang S; Hu Y; Li S; Jiang T; Qiang B; Peng X
Cell Death Differ; 2019 May; 26(5):796-811. PubMed ID: 29955125
[TBL] [Abstract][Full Text] [Related]
26. miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.
Wang H; Sun T; Hu J; Zhang R; Rao Y; Wang S; Chen R; McLendon RE; Friedman AH; Keir ST; Bigner DD; Li QJ; Wang H; Wang XF
J Clin Invest; 2014 Oct; 124(10):4489-502. PubMed ID: 25202981
[TBL] [Abstract][Full Text] [Related]
27. Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia.
Almiron Bonnin DA; Havrda MC; Lee MC; Liu H; Zhang Z; Nguyen LN; Harrington LX; Hassanpour S; Cheng C; Israel MA
Oncogene; 2018 Feb; 37(8):1107-1118. PubMed ID: 29155422
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
[TBL] [Abstract][Full Text] [Related]
29. Stemness of Normal and Cancer Cells: The Influence of Methionine Needs and SIRT1/PGC-1α/PPAR-α Players.
Siblini Y; Namour F; Oussalah A; Guéant JL; Chéry C
Cells; 2022 Nov; 11(22):. PubMed ID: 36429035
[TBL] [Abstract][Full Text] [Related]
30. Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression.
Jeon HM; Kim SH; Jin X; Park JB; Kim SH; Joshi K; Nakano I; Kim H
Cancer Res; 2014 Aug; 74(16):4482-92. PubMed ID: 24962027
[TBL] [Abstract][Full Text] [Related]
31. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
32. The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma.
Kijewska M; Kocyk M; Kloss M; Stepniak K; Korwek Z; Polakowska R; Dabrowski M; Gieryng A; Wojtas B; Ciechomska IA; Kaminska B
Oncotarget; 2017 Mar; 8(10):16340-16355. PubMed ID: 28030801
[TBL] [Abstract][Full Text] [Related]
33. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.
Strekalova E; Malin D; Weisenhorn EMM; Russell JD; Hoelper D; Jain A; Coon JJ; Lewis PW; Cryns VL
Breast Cancer Res Treat; 2019 May; 175(1):39-50. PubMed ID: 30712196
[TBL] [Abstract][Full Text] [Related]
34. ER stress inducer tunicamycin suppresses the self-renewal of glioma-initiating cell partly through inhibiting Sox2 translation.
Xing Y; Ge Y; Liu C; Zhang X; Jiang J; Wei Y
Oncotarget; 2016 Jun; 7(24):36395-36406. PubMed ID: 27119230
[TBL] [Abstract][Full Text] [Related]
35. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
[TBL] [Abstract][Full Text] [Related]
36. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
[TBL] [Abstract][Full Text] [Related]
37. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.
Venere M; Hamerlik P; Wu Q; Rasmussen RD; Song LA; Vasanji A; Tenley N; Flavahan WA; Hjelmeland AB; Bartek J; Rich JN
Cell Death Differ; 2014 Feb; 21(2):258-69. PubMed ID: 24121277
[TBL] [Abstract][Full Text] [Related]
39. HMGA2 sustains self-renewal and invasiveness of glioma-initiating cells.
Zhong X; Liu X; Li Y; Cheng M; Wang W; Tian K; Mu L; Zeng T; Liu Y; Jiang X; Yu L; Gao L; Zhou Y
Oncotarget; 2016 Jul; 7(28):44365-44380. PubMed ID: 27259253
[TBL] [Abstract][Full Text] [Related]
40. Actin cytoskeleton regulator Arp2/3 complex is required for DLL1 activating Notch1 signaling to maintain the stem cell phenotype of glioma initiating cells.
Zhang C; Hai L; Zhu M; Yu S; Li T; Lin Y; Liu B; Zhou X; Chen L; Zhao P; Zhou H; Huang Y; Zhang K; Ren B; Yang X
Oncotarget; 2017 May; 8(20):33353-33364. PubMed ID: 28380416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
